Literature DB >> 9072998

Persistence of airway hyperresponsiveness and viral antigen following respiratory syncytial virus bronchiolitis in young guinea-pigs.

F Riedel1, B Oberdieck, H J Streckert, S Philippou, T Krusat, W Marek.   

Abstract

Respiratory syncytial virus (RSV) bronchiolitis in infancy is known to be followed by chronic respiratory symptoms and airway hyperresponsiveness in a subgroup of patients. To further investigate the pathogenesis of RSV-induced chronic airway pathology, we infected young guinea-pigs at 4 weeks of age with RSV applied as an aerosol (n=30), and control guinea-pigs with virus-free culture medium (n=24). Infection was confirmed by positive antibody titre to RSV after 6 weeks, and by typical pathological changes of bronchiolitis after 1 week in six animals from each group. Airway hyperresponsiveness was measured weekly for 5 weeks by histamine challenge, using body-plethysmographic measurement of compressed air (CA). The provocative concentration of histamine producing significant airway obstruction (i.e. CA = 0.1 mL) (PC0.1 mL CA in mg x mL(-1)) was calculated from dose-response curves. Six weeks postinfection, the lungs were investigated for the presence of inflammation and of viral antigen by immunofluorescence and immunohistochemistry using a rabbit hyperimmune serum and monoclonal antibodies. Airway responsiveness was increased in the RSV group 1 week postinfection compared to the control group (PC0.1 mL CA median 2.50 vs >10 mg x mL(-1); p<0.001) and this persisted up to 5 weeks postinfection (PC0.1 mL CA median 1.61 vs >10 mg x mL(-1); p<0.001). During the same period, viral antigen persisted in the lungs of infected animals, although there was less inflammation at 6 weeks postinfection than at 1 week postinfection. In guinea-pigs, respiratory syncytial virus infection of the airways causes persistent airway hyperresponsiveness over a period of at least 5 weeks. During this time, viral antigen, but not inflammation, remains detectable in the lungs and might be responsible for ongoing airway hyperresponsiveness.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9072998

Source DB:  PubMed          Journal:  Eur Respir J        ISSN: 0903-1936            Impact factor:   16.671


  7 in total

Review 1.  Persistent RNA virus infections: do PAMPS drive chronic disease?

Authors:  Mary K McCarthy; Thomas E Morrison
Journal:  Curr Opin Virol       Date:  2017-02-17       Impact factor: 7.090

2.  A respiratory syncytial virus persistent-infected cell line system reveals the involvement of SOCS1 in the innate antiviral response.

Authors:  Junwen Zheng; Pu Yang; Yan Tang; Dongchi Zhao
Journal:  Virol Sin       Date:  2015-06-19       Impact factor: 4.327

3.  Respiratory syncytial virus persistence in macrophages upregulates Fcgamma receptors expression.

Authors:  Jorge Gaona; Carlos Santiago-Olivares; Enrique Ortega; Beatriz Gómez
Journal:  Viruses       Date:  2014-02-06       Impact factor: 5.048

Review 4.  The role of viruses in development or exacerbation of atopic asthma.

Authors:  J Schwarze; E W Gelfand
Journal:  Clin Chest Med       Date:  2000-06       Impact factor: 2.878

Review 5.  Response to infections in patients with asthma and atopic disease: an epiphenomenon or reflection of host susceptibility?

Authors:  Kristina M James; R Stokes Peebles; Tina V Hartert
Journal:  J Allergy Clin Immunol       Date:  2012-08       Impact factor: 10.793

Review 6.  Molecular and cellular mechanisms in the viral exacerbation of asthma.

Authors:  Sharyn Tauro; Yung-Chang Su; Sandra Thomas; Jürgen Schwarze; Klaus I Matthaei; Dijana Townsend; Ljubov Simson; Ralph A Tripp; Suresh Mahalingam
Journal:  Microbes Infect       Date:  2008-08-13       Impact factor: 2.700

7.  Amplified parallel antigen rapid test for point-of-care salivary detection of SARS-CoV-2 with improved sensitivity.

Authors:  Danny Jian Hang Tng; Khee Chee Soo; Bryan Chu Yang Yin; Jing Cao; Kwan Ki Karrie Ko; Kenneth Choon Meng Goh; Delia Xue Wen Chua; Yong Zhang; Melvin Lee Kiang Chua; Jenny Guek Hong Low; Eng Eong Ooi
Journal:  Mikrochim Acta       Date:  2021-12-06       Impact factor: 5.833

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.